Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects

被引：0
|
作者：
Chanan Shaul
Simcha Blotnick
Mordechai Muszkat
Meir Bialer
Yoseph Caraco
机构：
[1] Hadassah-Hebrew University Medical Center,Clinical Pharmacology Unit, Division of Medicine
[2] Hebrew University,Institute of Drug Research, School of Pharmacy, Faculty of Medicine
来源：
Molecular Diagnosis & Therapy | 2017年 / 21卷
关键词：
Warfarin; Variant Allele; Warfarin Dose; Oral Clearance; CYP2C9 Genotype;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：75 / 83
页数：8
相关论文
共 50 条
  • [1] CYP2C9 genetic polymorphisms and warfarin
    Redman, AR
    Dickmann, LJ
    Kidd, RS
    Goldstein, JA
    Ritchie, DM
    Hon, YY
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2004, 10 (02) : 149 - 154
  • [2] Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms
    Mark W. Linder
    Stephen Looney
    Jesse E. Adams
    Nancy Johnson
    Deborah Antonino-Green
    Nichole Lacefield
    Bonny L. Bukaveckas
    Roland Valdes
    Journal of Thrombosis and Thrombolysis, 2002, 14 : 227 - 232
  • [3] Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9
    Khaleqsefat, E.
    Khalaj-Kondori, M.
    Bonyadi, Jabbarpour M.
    Battaloglu, E.
    HIPPOKRATIA, 2017, 21 (02) : 93 - 96
  • [4] Warfarin dose adjustments based on CYP2C9 genetic polymorphisms
    Linder, MW
    Looney, S
    Adams, JE
    Johnson, N
    Antonino-Green, D
    Lacefield, N
    Bukaveckas, BL
    Valdes, R
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2002, 14 (03) : 227 - 232
  • [5] R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9
    Yong, Wei Peng
    Kim, Tae Won
    Undevia, Samir D.
    Innocenti, Federico
    Ratain, Mark J.
    EUROPEAN JOURNAL OF CANCER, 2009, 45 (11) : 1904 - 1908
  • [6] CYP2C9 Genotype-DependentWarfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R-and S-Warfarin and Their Oxidative Metabolites
    Flora, Darcy R.
    Rettie, Allan E.
    Brundage, Richard C.
    Tracy, Timothy S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (03) : 382 - 393
  • [7] Warfarin: CYP2C9 polymorphisms increase risk of bleeding events
    Reactions Weekly, 2002, 897 (1) : 4 - 4
  • [8] Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance
    Shaul, Chanan
    Blotnick, Simcha
    Adar, Liat
    Muszkat, Mordechai
    Bialer, Meir
    Caraco, Yoseph
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1187 - 1198
  • [9] Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin
    Myong-Jin Kim
    Anne N. Nafziger
    Angela D. M. Kashuba
    Julia Kirchheiner
    Steffen Bauer
    Andrea Gaedigk
    Joseph S. Bertino
    European Journal of Clinical Pharmacology, 2006, 62 : 431 - 436
  • [10] Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer
    Ruud, Ellen
    Holmstrom, Henrik
    Bergan, Stein
    Wesenberg, Finn
    PEDIATRIC BLOOD & CANCER, 2008, 50 (03) : 710 - 713
12345